Johnson Financial Group, Inc. Exelixis, Inc. Transaction History
Johnson Financial Group, Inc.
- $2.05 Billion
- Q4 2024
A detailed history of Johnson Financial Group, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Johnson Financial Group, Inc. holds 200 shares of EXEL stock, worth $7,014. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 200
-0.0%
Holding current value
$7,014
Previous $5,000
20.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding EXEL
# of Institutions
564Shares Held
251MCall Options Held
1.45MPut Options Held
1.13M-
Black Rock Inc. New York, NY33.5MShares$1.17 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.4MShares$1.03 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA23.4MShares$822 Million4.16% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.3MShares$536 Million0.8% of portfolio
-
State Street Corp Boston, MA11.4MShares$400 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.3B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...